MAXON
14.9.2021 18:17:08 CEST | Business Wire | Press release
Maxon , the developers of professional software solutions for motion designers and visual effects artists, today announced updates to nearly every application within the company’s Maxon One product offering. Cinema 4D R25 and Trapcode Suite 17 unveil significant new functionality, the VFX Suite 2 features the addition of the recently acquired Bang muzzle flare generator, the introduction of Redshift RT, a new rendering mode that provides near real-time rendering performance and multiple products have received essential compatibility and optimization updates for Apple Silicon-powered Macs, as well as support for Multi-Frame Rendering (MFR) in Adobe After Effects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005272/en/
This multi-product update release follows the company’s enhancements to many products released earlier this year, illustrating Maxon’s commitment to delivering consistent product development and superior value to the Maxon One offering.
Maxon One subscribers can immediately download all product updates via Maxon App, while subscribers to Cinema 4D , Red Giant Complete , Universe and Redshift also have immediate access to upgrades for each respective product. Anyone can begin a 14-day trial of the entire Maxon One offering from within Maxon App and experience for themselves all the great new features across the entire Maxon family of products.
“We’ve added a load of innovative functionality and valuable compatibilities to many of the products in Maxon One,” said Dave McGavran, Maxon CEO. “Our goal is to provide artists a frictionless creative experience with trailblazing technology.”
See Maxon One in Action on The 3D and Motion Design Show
Maxon will debut the features of Cinema 4D R25, Trapcode 17, VFX 2, Redshift RT and more during its two-day virtual event. Tune in online at 3DMotionShow.com on September 14th and 15th for exclusive presentations from industry-leading artists.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Its product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology, the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools, the high-end production, blazingly fast Redshift rendering solutions, and the intuitive forger mobile sculpting app.
Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From its popular, inclusive events to its free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to Maxon’s ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group .
Maxon Web Resources
Additional information on Maxon can be obtained as follows:
Website
Facebook
Twitter
YouTube
Instagram
LinkedIn
Maxon Showreel
All trademarks contained herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005272/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.11.6.2026 15:00:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, will be prominently featured at SLEEP 2026. The medtech company will showcase its innovative technology at booth #600, present clinical experience with their solution in 3 poster sessions, and host an educational symposium titled “Scaling PSG for the Next Decade: Expanding Utilization of High-Complexity Home Testing.” Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2026 conference. The medtech company will showcase this innovative solution at booth #600 during the largest annual sleep medicine conference, which brings together leading experts and innovators in the field. Furthermore, in anticipation of new CPT codes, Onera Health will host an educational symposium on Scaling PSG for the Next Decade: Expanding Utilization of High-
Xsolla to Meet With Mobile Game Developers and Publishers at Pocket Gamer Connects Barcelona 202611.6.2026 15:00:00 CEST | Press release
Company to Highlight Direct-to-Consumer Web Shop Solutions and Global Payments Infrastructure at Europe's Premier Mobile Gaming Conference Xsolla, a leading global video game commerce company, today announced its participation in Pocket Gamer Connects (PGC) Barcelona 2026, taking place June 15-16 at the Hyatt Regency Barcelona in Barcelona, Spain. Xsolla will be on the ground for meetings with mobile game developers, publishers, and strategic partners, bringing its direct-to-consumer commerce infrastructure to one of the most deal-focused events in the European games calendar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611487209/en/ Graphic: Xsolla Now in its second year, PGC Barcelona has quickly established itself as a destination conference for mobile game businesses, drawing more than 1,000 attendees from over 47 countries and facilitating thousands of structured business meetings through its dedicated matchmaking
IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 14:50:00 CEST | Press release
The system will enable advanced applications in optimization, simulation, and machine learning. IQM Radiance quantum computer, featuring a 54-qubit processing unit. The system is being integrated into Leonardo, one of the world's fastest supercomputers. This is the second IQM quantum computer to be operational in Italy. The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom